Navigation Links
ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease
Date:12/7/2009

MOUNTAIN VIEW, Calif., Dec. 7 /PRNewswire/ -- In addition to data released in late November, ChemoCentryx, Inc., announced today more data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease. While the earlier announcement concerned the Induction period of the study, new data from the Maintenance period of the study showed that a statistically significant number of patients receiving continuous therapy of Traficet-EN versus placebo for 36 weeks were in clinical remission of Crohn's disease, defined as a score of 150 points or less in the Crohn's Disease Activity Index (CDAI). At week 36, a statistically significant percentage of patients receiving Traficet-EN versus placebo were in corticosteroid-free remission. Traficet-EN continued to be safe and well-tolerated after extended use. Additionally, conclusive evidence was provided that the involvement of the CCR9 and its chemokine ligand (TECK) in inflammatory bowel disease (IBD) is not just restricted to the small bowel, but is relevant to inflammation of the large bowel as well.

The new Crohn's disease clinical remission findings, as well as the expanded understanding of the role of CCR9 and its ligand TECK in the gastrointestinal system (GI) tract, were highlighted in poster and oral presentations titled "PROTECT-1 Maintenance Phase Study Results Demonstrate Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease" and "CCR9 Inhibition in the Treatment of Colonic Inflammation" at the 2009 Advances in Inflammatory Bowel Diseases, Crohn's & Colitis Foundation's Clinical & Research Conference in Hollywood, Florida.

Traficet-EN is an orally-active antagonist of the chemokine receptor known as 'CCR9', which is selectively expressed by inflammatory T cells that migrate to the digestive t
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
2. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
3. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
4. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
5. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
6. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
7. Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution
8. Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis
9. NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
10. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
11. Pharmasset Reports Fiscal Year End 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... , Sept. 15, 2014  Valeant Pharmaceuticals International, Inc. ... its wholly owned subsidiary, Valeant Pharmaceuticals International, will redeem ... of its 6.75% Senior Notes due 2017, CUSIP Nos. ... 2014 and has mailed an irrevocable notice of redemption ... a copy of the irrevocable notice of redemption with ...
(Date:9/15/2014)... TAMPA, Fla. , Sept. 15, 2014 ... Dr. Steven Stanos with an expanded role ... program. Dr. Stanos, a nationally recognized physiatrist ... on topics related to rehabilitation and workers, compensation, is ... medicine by the American Board of Pain Medicine and ...
(Date:9/15/2014)... PDL BioPharma, Inc. (PDL) (NASDAQ: ... September 12, 2014, regular quarterly dividend payment of $0.15 per ... of September 5, 2014, the record date. ... portfolio of patents and royalty assets, consisting primarily of ... agreements with various biotechnology and pharmaceutical companies. PDL pioneered ...
Breaking Medicine Technology:Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 2myMatrixx Announces Expanded Role for Medical Director Steven P. Stanos, Jr., DO 2PDL BioPharma Completes Regular Quarterly Dividend Payment 2
... NJ, Aug. 18 /PRNewswire-Asia/ -- ... ... var shortURL = ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... On August 9, 2010 Massachusetts passed Chapter 283 ... Prescription Monitoring Program and furthering Substance Abuse Education and ... in Massachusetts that dispense schedule II, III, IV, or ... sale at each location. More info at http://www.mass.gov/legis/laws/seslaw10/sl100283.htm ...
Cached Medicine Technology:Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 2Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 3Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 4Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 5Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 6New Law Requires Pharmacies in Massachusetts to Carry Rx Lock Boxes 2
(Date:9/16/2014)... Louisiana (PRWEB) September 16, 2014 New ... an amazing new product for corporate wellness programs and ... Kit. , “In the past, cholesterol screening was ... large amount of products, variable SKUs and storage space ... “With our Universal Cholesterol Screening Kits, it’s easy: one ...
(Date:9/16/2014)... Pass, OR (PRWEB) September 16, 2014 ... is experiencing a major extended drought crisis that in ... survival. Grigg praises the many individuals who are dedicated ... fresh water policy solutions overlook large portion of the ... new, possibly worse crises.     , Grigg explained his, “total ...
(Date:9/16/2014)... 2014 Oxnard dentist and ... Dental Art Institute in Oxnard and Woodland Hills, Calif., ... weekend. , Dr. Jivraj, an expert in teeth restoration ... in his presentation “Clinical and Laboratory Aspects of ... p.m. Saturday, Sept. 20, at the Empire Landmark Hotel ...
(Date:9/16/2014)... On September 14, the HearStrong Foundation ... Bills Alumni Foundation VIP Tailgate event outside Ralph Wilson ... NFL Hall-of-Famer Joe DeLamielleure, who also experiences hearing ... her dedication in overcoming hearing difficulties to achieve her ... community to do the same. , Nominated by Hearing ...
(Date:9/16/2014)... DeLand, Florida (PRWEB) September 16, 2014 ... clinical trials being conducted in DeLand, FL can visit ... or contact them directly at (386) 785-2404. , Why ... of the most widespread viral diseases infecting mankind. While ... past, these colds still account for more annual visits ...
Breaking Medicine News(10 mins):Health News:New Line Medical Launches Universal Cholesterol Screening Kits 2Health News:Drought Solutions Overlook Too Many Factors Water Policy Expert Warns Sharon Kleyne 2Health News:Drought Solutions Overlook Too Many Factors Water Policy Expert Warns Sharon Kleyne 3Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 2Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 3Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 4Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 5Health News:The HearStrong Foundation and the Buffalo Bills Alumni Foundation Celebrated HearStrong Champion During 2014 Alumni Weekend 2Health News:Avail Clinical Research Is Looking for Healthy Adults Who Are Interested in Participating in a Common Cold Clinical Trial near Orlando, Florida 2Health News:Avail Clinical Research Is Looking for Healthy Adults Who Are Interested in Participating in a Common Cold Clinical Trial near Orlando, Florida 3
... the monotone of an instructor or insufficient rest the night ... trouble staying awake in class. Researchers have now found a ... awake during class, and it doesn't have anything to do ... alertness by applying acupressure at stimulation points to keep themselves ...
... Being one of the fastest progressing and spreading diseases of ... going on in this direction and a new study states ... to osteoarthritis. ,The study was conducted at ... the ability of an extract of pomegranate fruit against Interleukin-1b ...
... Vioxx, pain killer which was found to cause the death ... Merck Pharma the manufacturers of Vioxx were asked by the ... to Mrs. Ernst. Over 5 years, about 20 million people ... September 2004, after a clinical trial found irrefutable evidence that ...
... obstetricians urge their pregnant patients to exercise regularly, when ... ,The researcher from Saint Louis University School of ... September issue of a publication for obstetricians and gynecologists. ... exercise in women with healthy pregnancies results in no ...
... tiny delivery vehicles that can carry anticancer therapeutic ... genetic material constructed through nanotechnology, offering a potential ... This emerging branch of science is called nanomedicine. ... are assembled from three short pieces of ribonucleic ...
... through the scientific circles that soft trans fat-free margarines in ... disease. ,The study is one of the many aimed ... risk for coronary heart disease (CHD) was more closely associated ... fat-free margarines made from soybean and canola oil)(1). In fact, ...
Cached Medicine News:Health News:Pomegranate Juice Is Helpful In Arresting Osteoarthritis 2Health News:RNA Nanotechnology To Rescue Cancer Patients In Future 2Health News:PUFA Good For Heart: Gets The Scientific Seal 2
...
Adjustable wire speculum with 17 mm open blades. Lid tension adjustable throughout procedure with thumb screw control. Shaft angled 45 degrees. Manufactured in titanium....
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Open 15 mm blades with lifting wings manipulation of I/A cannulas, knives, instrumentation, etc. Screwlocking mechanism. Dull finish....
Medicine Products: